Updates with background paragraph 2 onwards
June 17 (Reuters) - Caris Life Sciences raised $494.1 million in its Nasdaq initial public offering, the cancer diagnostic firm said on Tuesday, amid a rebound in the IPO market.
Investors have shown renewed interest in U.S. IPOs in recent weeks, following a prolonged slowdown triggered by uncertainties over President Donald Trump's tariff policies.
The recent surge in listing activity and strong market debuts of virtual healthcare providers Omada OMDA.O and Hinge Health HNGE.N have encouraged other companies in the sector to move forward with their listing plans.
The Irving, Texas-based company sold roughly 23.5 million shares, at $21 apiece, above its increased marketed price range of between $19 and $20.
Caris is an artificial intelligence-based precision medicine firm that helps diagnose cancer through tumor profiling and blood-based cancer diagnostics.
Founded in 2008 by CEO David Halbert, Caris generates revenue mainly from its tissue-based molecular profiling, which helps determine the appropriate cancer therapy for each case.
Caris will start trading on the Nasdaq on Wednesday under the symbol "CAI".
BofA Securities, J.P. Morgan, Goldman Sachs and Citigroup are the lead underwriters.
(Reporting by Prakhar Srivastava and Gursimran Kaur in Bengaluru; Editing by Alan Barona and Mrigank Dhaniwala)
((GursimranKaur.Mehar@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。